165 related articles for article (PubMed ID: 6752017)
1. In vivo crevicular leukocyte response to a chemotactic challenge: inhibition by experimental diabetes.
Golub LM; Nicoll GA; Iacono VJ; Ramamurthy NS
Infect Immun; 1982 Sep; 37(3):1013-20. PubMed ID: 6752017
[TBL] [Abstract][Full Text] [Related]
2. The investigation of the ultrastructural neutrophil changes in alloxan-induced diabetes in rats: response to a chemotactic challenge.
Ozsoy N; Bostanci H; Ayvali C
Cell Biochem Funct; 2004; 22(2):81-7. PubMed ID: 15027096
[TBL] [Abstract][Full Text] [Related]
3. In vivo assay of crevicular leukocyte migration. Its development and potential applications.
Iacono VJ; Singh S; Golub LM; Ramamurthy NS; Kaslick R
J Periodontol; 1985 Nov; 56(11 Suppl):56-62. PubMed ID: 2934540
[TBL] [Abstract][Full Text] [Related]
4. In vivo crevicular leucocyte response in humans to a chemotactic challenge. Effects of periodontal diseases.
Singh S; Golub LM; Iacono VJ; Ramamurthy NS; Kaslick R
J Periodontol; 1984 Jan; 55(1):1-8. PubMed ID: 6363671
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory polymorphonuclear neutrophil leukocytes; orientation, chemotactic, locomotor and phagocytic capabilities of neutrophils from the human gingival crevice.
Scully C; Wilkinson PC
J Clin Lab Immunol; 1985 Jun; 17(2):69-73. PubMed ID: 3900409
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Assay of Crevicular Leukocyte Migration: Its Development and Potential Applications.
Iacono VJ; Singh S; Golub LM; Ramamurthy NS; Kaslick R
J Periodontol; 1985 Nov; 56 Suppl 11S():56-62. PubMed ID: 29538942
[TBL] [Abstract][Full Text] [Related]
7. Comparison of neutrophil chemotactic response in diabetic patients with mild and severe periodontal disease.
Manouchehr-Pour M; Spagnuolo PJ; Rodman HM; Bissada NF
J Periodontol; 1981 Aug; 52(8):410-5. PubMed ID: 7021793
[No Abstract] [Full Text] [Related]
8. Two neutrophil populations in human blood with different chemotactic activities: separation and chemoattractant binding.
Harvath L; Leonard EJ
Infect Immun; 1982 May; 36(2):443-9. PubMed ID: 7085067
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of leukocyte chemotaxis by serum factor in diabetes mellitus: selective depression of cell responses mediated by complement-derived chemoattractants.
Sannomiya P; Pereira MA; Garcia-Leme J
Agents Actions; 1990 Jun; 30(3-4):369-76. PubMed ID: 2167002
[TBL] [Abstract][Full Text] [Related]
10. Influence of gingival crevicular washing on the expression of polymorphonuclear leukocyte membrane receptors before and after periodontal therapy.
Di Murro C; Fattorossi A; Paolantonio M; Pedrazzoli V; Sergi G; Casciaro A; D'Amelio R; Cattabriga M
J Clin Periodontol; 1995 Jul; 22(7):578-83. PubMed ID: 7560242
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of calcium-dependent chemotactic factor activatable esterase activity in human neutrophils: relationship with chemotaxis and chemotactic deactivation.
Mehta J; Mandell B; Kleyman T; Spilberg I
Inflammation; 1981 Jun; 5(2):89-101. PubMed ID: 7275278
[TBL] [Abstract][Full Text] [Related]
12. Chemotactic factor receptor modulation and cytoskeletal structures.
Spilberg I; Mehta J
Infect Immun; 1981 Apr; 32(1):268-72. PubMed ID: 7216488
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation.
Solomkin JS; Jenkins MK; Nelson RD; Chenoweth D; Simmons RL
Surgery; 1981 Aug; 90(2):319-27. PubMed ID: 7256544
[TBL] [Abstract][Full Text] [Related]
14. The response of human sulcular leucocytes to a chemotactic challenge. A new in vivo assay.
Golub LM; Iacono VJ; Nicoll G; Ramamurthy N; Kaslick RS
J Periodontal Res; 1981 Mar; 16(2):171-9. PubMed ID: 6453980
[No Abstract] [Full Text] [Related]
15. Role of filter-bound IgA in inhibiting polymorphonuclear leukocyte chemotaxis.
Schröder JM; Christophers E
Immunobiology; 1983 Mar; 164(2):127-35. PubMed ID: 6852861
[TBL] [Abstract][Full Text] [Related]
16. Effects of human complement component 1 inactivator on neutrophil chemotaxis and chemotactic deactivation.
Patrick RA; Hollers JC; Liu DY; Giese BH; Smith CW
Infect Immun; 1980 Jun; 28(3):700-7. PubMed ID: 7399690
[TBL] [Abstract][Full Text] [Related]
17. Phloretin is a potent inhibitor of rabbit neutrophil activation by chemotactic factors.
Shefcyk J; Molski TF; Volpi M; Naccache PH; Sha'afi RI
Biochim Biophys Acta; 1983 Feb; 728(1):97-102. PubMed ID: 6830775
[TBL] [Abstract][Full Text] [Related]
18. Chemotactic deactivation of human neutrophils: relationship to loss of cytotaxin receptor function and temporal nature of the phenomenon.
Nelson RD; Fiegel VD; Herron MJ; Simmons RL
J Reticuloendothel Soc; 1980 Sep; 28(3):285-94. PubMed ID: 7411541
[No Abstract] [Full Text] [Related]
19. A possible role for cold insoluble globulin in chemotactic factor mediated polymorphonuclear leukocyte adherence to plastic.
Spagnuolo PJ; Lederman MM; Schiltz J; Ellner J; Culp L
Biochem Biophys Res Commun; 1982 May; 106(2):471-8. PubMed ID: 7049175
[No Abstract] [Full Text] [Related]
20. Receptor-directed inhibition of chemotactic factor-induced neutrophil hyperactivity by pyrazolon derivatives. Definition of a chemotactic peptide antagonist.
Dahinden C; Fehr J
J Clin Invest; 1980 Nov; 66(5):884-91. PubMed ID: 7430350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
